The pooled effects showed no significant difference in the rate of COVID-19 mortality (RR: 1.72; 95% CI: 0.60-4.97; P = 0.32) (Figure 3C) between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics. Here, IL17A is linked to psoriasis.